1/5/2012

Halo Therapeutics' drug candidate HT-100, or halofuginone, secured orphan-drug designation from the FDA. The drug, which regenerates muscle fiber in patients with Duchenne muscular dystrophy, will move into midstage development this year, said Halo CEO Marc Blaustein.

Related Summaries